Merck Appoints Jayesh Parkar as Head of Excipients and Biopharma Chemicals for APAC

As Asia-Pacific pharmaceutical manufacturing continues to scale, Merck has appointed Jayesh Parkar as Head of Excipients and Biopharma Chemicals for the APAC region, signalling a deliberate push to deepen its commercial presence across one of the industry's fastest-growing supply corridors.

In the role, Parkar is tasked with driving commercial growth, expanding customer partnerships, and accelerating uptake of Merck's excipient and biopharma chemical portfolio across the region. For procurement leads and formulation teams at APAC-based manufacturers, the appointment points to increased regional engagement from a major excipient supplier at a time when raw material qualification and supply continuity remain active pressure points in GMP-compliant operations.

The excipient supply landscape in APAC has grown more complex as manufacturers face tighter scrutiny under ICH Q10-aligned quality systems and evolving pharmacopoeial standards. A regionally embedded leadership structure from a global supplier can shorten response cycles on technical queries, regulatory documentation support, and change notification management, all of which carry direct implications for validated processes and site master files.

Parkar's mandate to accelerate adoption of innovative excipient solutions also warrants attention from formulation development teams working on biologics and complex drug products, where excipient functionality and biopharma-grade chemical specifications intersect with sterility assurance and process validation requirements.

The degree to which Merck converts this leadership investment into measurable supply reliability and technical support depth across APAC manufacturing hubs will be a concrete indicator of the region's strategic weight in the company's broader life science materials business.

Source: Media4Growth via Indian Pharma Post, 9 August 2026.